Filgrastim Articles
Small-Molecule G-CSF Developed
16 July 1998
Nicholas Piramal To Focus On Pharma Business
27 April 1998
US Quarterly Financial Results Round-Up
23 April 1998
Amgen's Neupogen OKed For AML
8 April 1998
Roche Sales Soar In 1st Quarter 1998
7 April 1998
Strong Growth For US Drug Firms In 1997
28 January 1998
New Products In 1998; A Look Ahead
6 January 1998
First Approval For Genetics Institute's Neumega
4 December 1997
US 3rd Qtr Corporate Results Round-Up
30 October 1997
Amgen's Infergen Approved; 1st New Product In 6 Years
9 October 1997
FDA Panel: Neupogen Comments
31 July 1997
Solid Growth For US Firms Despite Strong $
24 July 1997
Outlook Favorable For Global Health Care
23 June 1997
Roche/Corange Deal Comfirms Global Strategy
9 June 1997
Higher Biotech Earnings But Investors Stay Cool
19 May 1997
EPS Rises 27% At Amgen In 1st Qtr
22 April 1997
First-Quarter Sales At Roche Up 18%
21 April 1997
Significant Increases For US Drug Firms In 1996
3 February 1997
Amgen's BDNF Fails In Clinical Trials For ALS
20 January 1997
Profits Rise 23% At Amgen
21 October 1996
Investment, Profitability And Biotechnology
14 October 1996
High French Hospital Spending Hits Local Drugmakers
12 August 1996
Dilemma For Imported Drugs In China
5 August 1996
US Drug Majors See 2nd-Half Double-Digit Growth
29 July 1996
US Firms' Strong 1st Qtr Lifts Share Prices
29 April 1996
Amgen Entering New Product Cycle
1 April 1996
Neupogen Approved In UK For Neutropenia In AIDS
18 March 1996
Losec "Will Be The World's Top-Selling Drug In 2000"
26 February 1996
Mixed Earnings But Strong Sales For US Companies
12 February 1996
FDA Year-End Approvals Round-Up
8 January 1996
Rhone-Poulenc Rorer's Granocyte Perhaps More Potent Than Neupogen
18 December 1995
Neupogen And Leukine Backed For Peripheral Blood Transplantation
20 November 1995
Consistent 9% Growth In World Pharma Sales
13 November 1995
New York Stock Comment
30 October 1995
US Drug Cos Reveal Strong Growth In 1995 3rd Qtr
30 October 1995
Roche Ahead Of Forecasts in 1995 First Half
4 September 1995
Simplifying Stem Cell Harvesting
7 August 1995
Strong International Sales For US Cos In 2nd Qtr
31 July 1995
The Biopharmaceutical Industry To Come
17 July 1995
Medarex' MDX-210 Plus Neupogen
19 June 1995
Amgen Starts Platelet Growth Factor Trials
8 May 1995
Progress In 1994 For Amgen And Cellcor
13 February 1995
Roche's Sales Ahead, Profit Growth Expected
23 January 1995
CPMP Approves BMT Replacement Approach
16 January 1995
Amgen Approval For Plant
9 January 1995
Neupogen Approved For SCN In USA
9 January 1995
NEW YORK STOCK COMMENT
12 December 1994
US 3rd Quarter Shows Growth Despite Pressures
24 October 1994
US Biotech Cos Top Earnings At 1st Half
25 July 1994
GERMAN REFORM A BLIP SAYS ROCHE
11 July 1994
NEUPOGEN APPROVED FOR BMT IN USA
27 June 1994
US CHEMICAL/DRUG COs SHOW 1st QTR GROWTH
9 May 1994
RISING SWISS FRANC HITS ROCHE SALES
18 April 1994
IMMUNEX AIMS FOR THREE DRUGS IN CLINIC IN 1994
21 February 1994
NEW STOCK COMMENT
14 February 1994
RESTRUCTURING CHARGES DEPRESS LILLY AND E KODAK
14 February 1994
WORLD HEMATOLOGY MARKET FORECASTS
24 January 1994
LENOGRASTIM LAUNCHED IN UK
17 January 1994
BETAFECTIN STARTS PHASE III TRIALS
17 January 1994
ROCHE RECORDS 11% INCREASE IN '93 SALES
17 January 1994
SANDOZ UNVEILS IL-6 TRIAL DATA
20 December 1993
DRUGS FOR CANCER IMMUNOLOGY IN 1992
29 November 1993
COMBINING SCF AND G-CSF THERAPY
15 November 1993
CURRENCY EXCHANGE FACTOR HITS US 3rd QTR
8 November 1993
NEW YORK STOCK COMMENT
25 October 1993
FIRST NINE MONTHS STRONG FOR ROCHE
25 October 1993
FILGRASTIM BACKED FOR NEW INDICATION
11 October 1993
PMA WARNING ON FUTURE OF BIOTECHNOLOGY
27 September 1993
AUSTRALIAN NO TO AMGEN'S NEUPOGEN
27 September 1993
AMGEN KIRIN JOINT AGREEMENT
6 September 1993
NEW YORK STOCK COMMENT
16 August 1993
AMGEN SETS UP HONG KONG/CHINA BASE
16 August 1993
BIOTECH PRODUCTS INUS DEVELOPMENT
26 July 1993
NICHE MARKETING IN THE BIOTECH INDUSTRY
26 July 1993
ROCHE PHARMA HEALTHY IN 1st HALF
19 July 1993
PHARMA DIRECTION FOR BRITISH BIO-TECHNOLOGY
19 July 1993
LENOGRASTIM GIVEN CPMP PANEL BACKING
12 July 1993
NEW YORK STOCK COMMENT
31 May 1993
NEW YORK STOCK COMMENT
24 May 1993
STRONG GROWTH BY US PHARMA COs IN 1st QTR
10 May 1993
ROCHE FORESEES GOOD OUTLOOK FOR 1993
3 May 1993
BREAST CANCER US RESEARCH UPDATE
26 April 1993
KIRIN EXPANDS INDICATIONS
19 April 1993
PRICE FLEXIBILITY AND THE DRUG INDUSTRY
12 April 1993
FILGRASTIM RESULTS
29 March 1993
NEW YORK STOCK COMMENT
22 March 1993
PHARMACEUTICAL DESIGN: EPITOPE SELECTION
15 March 1993
AUSTRALIA TO RESTRICT NEUPOGEN
15 March 1993
IMCLONE HEADING FOR COMMERCIALIZATION
1 March 1993
US COMPANIES IN BIOTECH LINK-UP
18 January 1993
ROCHE 1992 SALES RISE BY 13%
18 January 1993
ISRAEL CONSIDERS KORATH INCLUSIONS
4 January 1993
ABPI CODE OF PRACTICE LATEST REPORT
21 December 1992
IN DEFENSE OF BIOTECHNOLOGY
7 December 1992
LEUCOMAX LAUNCH IN UK
9 November 1992
FILGRASTIM: NO PLACE IN ABMT?
12 October 1992
FOCUS ON IVAX PRODUCT PIPELINE
12 October 1992
USE OF GROWTH FACTORS IN AIDS MANAGEMENT
7 September 1992
GOOD GROWTH FOR US COMPANIESCONTINUES FOR US COs
3 August 1992
ABPI CODE OF CONDUCT REPORT
3 August 1992
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
